The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. (Q38102596)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Kathya Rivera

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Romina Lomonaco

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Kenneth Cusi

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

published in

Current diabetes report

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

329-341

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23625197%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11892-013-0378-8

29 February 2020

exact match

0 references

cites work

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Fat and beyond: the diverse biology of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

(How) can we prevent type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of pioglitazone on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Skeletal consequences of thiazolidinedione therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinediones and fractures: evidence from translating research into action for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Risk of fracture with thiazolidinediones: disease or drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone prevents smoking carcinogen-induced lung tumor development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Cell death is induced by ciglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, independently of PPARγ in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Use of thiazolidinedione and cancer risk in Type 2 diabetes: the Hong Kong diabetes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Menstrual cycle irregularity and risk for future cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Metformin for the treatment of the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Clomiphene, Metformin, or Both for Infertility in the Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

A prospective randomized trial comparing the clinical and endocrinological outcome with rosiglitazone versus laparoscopic ovarian drilling in patients with polycystic ovarian disease resistant to ovulation induction with clomiphene citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Features, diagnosis, and treatment of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-013-0378-8

ACOG Practice Bulletin No. 108: Polycystic ovary syndrome

21 January 2018

1 reference

12 December 2020

Thiazolidinediones (TZDs) affect osteoblast viability and biomarkers independently of the TZD effects on aromatase

1 reference

12 December 2020

Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.

1 reference

12 December 2020

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes

1 reference

12 December 2020

Pioglitazone and Rosiglitazone Have Different Effects on Serum Lipoprotein Particle Concentrations and Sizes in Patients With Type 2 Diabetes and Dyslipidemia

1 reference

12 December 2020

From the Food and Drug Administration

1 reference

12 December 2020

Reduction in Hematocrit and Hemoglobin Following Pioglitazone Treatment is not Hemodilutional in Type II Diabetes Mellitus

1 reference

12 December 2020

Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis

1 reference

12 December 2020

The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study

1 reference

12 December 2020

Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes

1 reference

12 December 2020

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus

1 reference

12 December 2020

Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome

1 reference

12 December 2020

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

1 reference

12 December 2020

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

1 reference

12 December 2020